首页 文献索引 SCI期刊 AI助手
首页 正文

Clinical Trial Journal for immunotherapy of cancer. 2021 Aug;9(8):e002757. doi: 10.1136/jitc-2021-002757 Q110.62025

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

关于西米普利单抗治疗晚期皮肤鳞状细胞癌II期研究的综合分析：随访延长后的疗效及生活质量分析 翻译改进

Danny Rischin  1, Nikhil I Khushalani  2, Chrysalyne D Schmults  3, Alexander Guminski  4, Anne Lynn S Chang  5, Karl D Lewis  6, Annette M Lim  7, Leonel Hernandez-Aya  8, Brett G M Hughes  9, Dirk Schadendorf  10, Axel Hauschild  11, Alesha A Thai  12, Elizabeth Stankevich  13, Jocelyn Booth  13, Suk-Young Yoo  13, Siyu Li  13, Zhen Chen  13, Emmanuel Okoye  13, Chieh-I Chen  13, Vera Mastey  13, Medha Sasane  14, Israel Lowy  13, Matthew G Fury  13, Michael R Migden  15

作者单位 +展开

作者单位

  • 1 Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia danny.rischin@petermac.org.
  • 2 Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • 3 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • 4 Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • 5 Department of Dermatology, Stanford University School of Medicine, Redwood City, California, USA.
  • 6 Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.
  • 7 Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.
  • 8 Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri, USA.
  • 9 Department of Cancer Care Services, Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, Queensland, Australia.
  • 10 Department of Dermatology, University Hospital Essen; German Cancer Consortium, Essen, Germany.
  • 11 Department of Dermatology, Schleswig-Holstein University Hospital, Kiel, Germany.
  • 12 Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • 13 Regeneron Pharmaceuticals, Tarrytown, New York, USA.
  • 14 Sanofi, Bridgewater Township, New Jersey, USA.
  • 15 Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • DOI: 10.1136/jitc-2021-002757 PMID: 34413166

    摘要 Ai翻译

    Background: To provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL). Methods: Patients received cemiplimab 3 mg/kg every 2 weeks (group 1, metastatic CSCC [mCSCC], n... ...点击完成人机验证后继续浏览
    Copyright © Journal for immunotherapy of cancer. 中文内容为AI机器翻译，仅供参考！

    相关内容

    期刊名：Journal for immunotherapy of cancer

    缩写：J IMMUNOTHER CANCER

    ISSN：N/A

    e-ISSN：2051-1426

    IF/分区：10.6/Q1

    文章目录 更多期刊信息

    全文链接
    官方链接
    PMC全文
    引文链接
    复制
    已复制！
    推荐内容
    Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis